Table 2 Mean annual age-standardiseda incidence per 100,000 mid-year population (95% confidence interval)
Type of sarcomab | 1982–87 | 1988–93 | 1994–99 | 2000–05 | 2006–11 | 2012–16 | Cases |
|---|---|---|---|---|---|---|---|
Soft tissue sarcoma | 5.4 (4.7–6) | 5.6 (5–6.2) | 6 (5.4–6.6) | 5.9 (5.3–6.4) | 5.9 (5.5–6.4) | 7.2 (6.7–7.8) | 3024 |
Soft tissue sarcoma of head and neck | 0.3 (0.1–0.5) | 0.2 (0.1–0.3) | 0.3 (0.2–0.4) | 0.4 (0.3–0.6) | 0.2 (0.1–0.3) | 0.3 (0.2–0.4) | |
Soft tissue sarcoma of limbs | 1.2 (0.9–1.5) | 1.1 (0.8–1.4) | 1.3 (1–1.5) | 1.2 (1–1.4) | 1.7 (1.4–2) | 2.3 (2–2.6) | |
Soft tissue sarcoma of superficial trunk | 0.3 (0.1–0.4) | 0.4 (0.2–0.6) | 0.6 (0.4–0.8) | 0.6 (0.4–0.8) | 0.5 (0.4–0.7) | 0.7 (0.6–0.9) | |
Soft tissue sarcoma of mediastinum | 0.1 (0–0.1) | 0 (0–0.1) | 0 (0–0.1) | 0 (0–0.1) | 0 (0–0) | 0.1 (0–0.1) | |
Soft tissue sarcoma of breast | 0.4 (0.2–0.5) | 0.1 (0–0.1) | 0.2 (0.1–0.4) | 0.2 (0.1–0.3) | 0.2 (0.1–0.3) | 0.3 (0.2–0.4) | |
Soft tissue sarcoma of uterus | 0.7 (0.4–1) | 0.9 (0.6–1.2) | 0.9 (0.6–1.2) | 1 (0.7–1.3) | 0.8 (0.6–1) | 0.9 (0.6–1.1) | |
Other soft tissue sarcomas of genitourinary tract | 0.2 (0.1–0.3) | 0.3 (0.2–0.4) | 0.2 (0.1–0.3) | 0.2 (0.1–0.3) | 0.3 (0.2–0.4) | 0.1 (0–0.2) | |
Soft tissue sarcoma of viscera | 0.7 (0.5–0.9) | 0.7 (0.5–1) | 0.5 (0.3–0.7) | 0.3 (0.2–0.4) | 0.3 (0.2–0.4) | 0.4 (0.2–0.5) | |
Soft tissue sarcoma of paratestis | 0.2 (0–0.4) | 0.2 (0–0.4) | 0.2 (0–0.3) | 0.1 (0–0.2) | 0.1 (0–0.1) | 0.1 (0–0.2) | |
Soft tissue sarcoma of retroperitoneum and peritoneum | 0.4 (0.2–0.6) | 0.5 (0.3–0.7) | 0.5 (0.3–0.6) | 0.3 (0.1–0.4) | 0.4 (0.3–0.5) | 0.4 (0.3–0.5) | |
Soft tissue sarcoma of pelvis | 0.2 (0.1–0.4) | 0.3 (0.2–0.4) | 0.3 (0.1–0.4) | 0.2 (0.1–0.3) | 0.3 (0.2–0.4) | 0.3 (0.2–0.4) | |
Soft tissue sarcoma of skin | 0.9 (0.6–1.2) | 1.1 (0.8–1.3) | 1.1 (0.9–1.4) | 1.3 (1.1–1.6) | 1 (0.8–1.1) | 1.4 (1.1–1.6) | |
Soft tissue sarcoma of brain and other parts of the nervous system | 0.1 (0–0.2) | 0.2 (0.1–0.2) | 0.1 (0–0.2) | 0.1 (0.1–0.2) | 0.3 (0.2–0.4) | 0.2 (0.1–0.3) | |
Embryonal rhabdomyosarcoma of soft tissue | 0.1 (0–0.1) | 0 (0–0) | 0 (0–0) | 0.1 (0–0.1) | 0.1 (0–0.1) | 0 (0–0) | |
Ewing’s family tumours of soft tissue | 0 (0–0.1) | 0 (0–0.1) | 0.2 (0.1–0.3) | 0.2 (0.1–0.3) | 0.1 (0.1–0.2) | 0.2 (0.1–0.2) | |
Bone sarcoma | 0.9 (0.7–1.2) | 1.1 (0.9–1.3) | 1 (0.8–1.3) | 0.9 (0.7–1.1) | 1 (0.8–1.2) | 1 (0.8–1.1) | 595 |
Osteogenic sarcoma | 0.3 (0.2–0.5) | 0.3 (0.2–0.4) | 0.3 (0.2–0.4) | 0.3 (0.2–0.3) | 0.2 (0.1–0.3) | 0.3 (0.2–0.4) | |
Chondrogenic sarcoma | 0.2 (0.1–0.4) | 0.4 (0.2–0.5) | 0.3 (0.2–0.4) | 0.2 (0.1–0.3) | 0.3 (0.2–0.5) | 0.2 (0.1–0.3) | |
Notochordal sarcomas, chordoma | 0.1 (0–0.2) | 0.1 (0–0.2) | 0.1 (0–0.2) | 0.1 (0–0.2) | 0 (0–0) | 0.1 (0–0.1) | |
Ewing’s family of tumours | 0.1 (0.1–0.2) | 0.1 (0.1–0.2) | 0.1 (0–0.2) | 0.1 (0.1–0.2) | 0.1 (0–0.2) | 0.1 (0.1–0.2) | |
Other high grade sarcomas (fibrosarcoma, malignant fibrous histiocytoma) | 0.1 (0–0.2) | 0.1 (0–0.1) | 0 (0–0.1) | 0 (0–0) | 0 (0–0.1) | 0 (0–0.1) | |
Gastrointestinal stromal sarcoma | 0 (0–0) | 0 (0–0.1) | 0.5 (0.3–0.7) | 0.7 (0.5–0.9) | 0.7 (0.5–0.8) | 0.6 (0.5–0.8) | 223 |
Kaposi’s sarcoma | 0.3 (0.1–0.4) | 0.6 (0.4–0.7) | 0.4 (0.2–0.5) | 0.3 (0.2–0.4) | 0.2 (0.1–0.3) | 0.1 (0.1–0.2) | 147 |
Sarcoma (total) | 6.6 (5.9–7.3) | 7.3 (6.6–8) | 7.9 (7.2–8.5) | 7.8 (7.2–8.4) | 7.8 (7.2–8.3) | 9 (8.4–9.6) | 3989 |
Female breast cancer | 115.2 (111–119.4) | 130.3 (126.3–134.4) | 144.6 (140.7–148.5) | 146.1 (142.5–149.6) | 146.3 (143–149.5) | 162.4 (158.9–165.9) | 35,932 |
Colorectal cancer | 84.6 (81.7–87.4) | 85.4 (82.9–88) | 88.4 (86–90.8) | 88.3 (86.1–90.4) | 84.4 (82.4–86.3) | 71.9 (70.1–73.6) | 34,846 |
Lung Cancer | 75.2 (72.5–77.8) | 70.8 (68.5–73.1) | 69.5 (67.4–71.6) | 68.2 (66.3–70.2) | 66.2 (64.5–67.9) | 63.4 (61.7–65.1) | 27,857 |
Prostate cancer | 130.9 (124.6–137.2) | 182.3 (176–188.7) | 224.8 (218.9–230.7) | 214.2 (209.1–219.3) | 264.3 (259.3–269.2) | 227.6 (223–232.1) | 40,802 |